![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 03, 2011 2:12:55 PM
Being re-imbursable in the Netherlands is all together a positive point, i.e. the product has become a mainstream drug. However, major acceptance might be an issue for a (long/some ?) while. Also, volumes in the Dutch market will never make BIEL a really big company.
The point is that the Dutch distributor is doing a good job (see also the miracle stories about the healing diabetes wounds), while this contrasts sharply with the poor job BIEL is doing in their home market (just to name a few: poor PR, scrappy design and/or packaging, working together with shady people like JN...need I go on ???)
Therefor ending on a negative note...
Unless BIEL starts working professionally we're a long way off the hoped-for levels in PPS
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM